Jean-Marie Michot

31PUBLICATIONS
153CO-AUTHORS
Predictive and prognostic markersMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Sep 23, 2026
Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trials.

|Dec 23, 2025
Multicenter Analysis of General presentations and Imaging features in Cerebral MUCORmycosis (MAGICMUCOR): toward different entities.

Clémentine de La Porte, Corentin Provost, Anne Coste

|Sep 24, 2025
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.

Romain Guitton, Ariane Laparra, Noemie Chanson

|Aug 04, 2025
Diaphragmatic Palsy Due to a Paraneoplastic Autoimmune Syndrome Revealed by Checkpoint Inhibitors.

Jean-Baptiste Destival, Jean-Marie Michot, Cécile Cauquil

|Aug 04, 2025
Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.

Jean-Marie Michot, Zsofia Balogh, Jennifer R Brown

|Apr 01, 2025
Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Thomas Hueso, Justin Cagnat, Kaïssa Ouali

Pageof 6

Frequent Collaborators

4 joint publications

Aurelien Marabelle

3 joint publications

Capucine Baldini

3 joint publications

Antoine Hollebecque

3 joint publications

Francois-Xavier Danlos